Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines;Dépistage des patients déficitaires en dihydropyrimidine déhydrogénase avant traitement par fluoropyrimidines

Therapie

Volumn 62, Issue 2, 2007, Pages 99-103

  Gamelin, Erick ^a   Boisdron Celle, Michèle ^a   Morel, Alain ^a  

^a CENTRE PAUL PAPIN   (France)

Author keywords

5 fluorouracil; Dihydropyrimidine dihydrogenase; Fluoropyrimidines; Genotyping; Toxicity

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROPYRIMIDINE; FLUOROURACIL; UFT; URACIL; 1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TEGAFUR; UNCLASSIFIED DRUG;

CATABOLISM; CONFERENCE PAPER; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; ARTICLE; ENZYMOLOGY; GENETICS; NEOPLASM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; NEOPLASMS; TEGAFUR; URACIL;

EID: 34548629058     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007023     Document Type: Conference Paper

References (20)

1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
2. Douillard JY, Cunningham D, Roth, AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7
3. Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. New Engl J Med 1985; 313: 245 [letter]
4. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-Fluorouracil clinical toxicity and tumor resistance. Clin Can. Res 1999; 5: 2672-3
5. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-53
6. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication influorouracil chemotherapy. Cancer Res 1993; 53: 5433-8
7. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase (biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity). J Clin Invest 1988; 81: 47-51
8. Johnson MR , Hageboutros A, Wang K. Life-threatening toxicity in a dihydropyrimidine dehydrogenase deficient patient after treatment with topical 5-Fluorouracil. Clin Cane Res 1999; 5: 2006-11
9. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation. Int. J Cancer 2002; 101: 253-8
10. Van Kuilenburg ABP, Abreu R, Van Gennip A. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40: 41-5
11. Mc Leod H., Collie-Duguid ESR, Vrecken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8: 455-9
12. Van Kuilenburg ABP, Haasjes J, Van Gennip H, et al. Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Can Res 2000; 6: 4705-12
13. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation. Int J Cancer 2002; 101: 253-8
14. Morel A, Boisdron-Celle M, Fey L, Soulié P, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms (SNP) upon 5-fluorouracil tolerance in a prospective clinical study in a french Caucasian population. Mol Cancer Ther 2006; 5: 2895-904
15. Van Gennip AH, Van Bree-Blom EJ, Wadman SK, et al. HPLC of urinary pyrimidines for the evaluation of primary and secondary abnormalities of pyrimidine metabolism. In: Hawk GL, ed. Biological biomedical applications of liquid chromatography, III. New York and Basel, Marcel Dekker Inc, 1982, pp 285-296
16. Gamelin E, Boisdron-Celle M, Lana F, Robert J. Simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites. J Liq Chrom Rel Technol 1997; 20: 3155-72
17. Gamelin E, Boisdron-Celle M, Guérin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, and 5-fluorouracil pharmacokinetic parameters and tolerance in patients with advanced colorectal cancer. A potential interest for predicting 5-FU toxicity and for determining optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105-10
18. Remaud G, Boisdron-Celle M, Hameline C, et al. An accurate Dihydrouracil/Uracil determination using improved High Performance Liquid Chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B 2005; 823 (2): 98-107
19. Morel A, Boisdron-Celle M, Fey L, Lainé-Cessac P, et al. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with lethal outcome after 5-fluorouracil administration and determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007; 40: 11-7
20. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluororuacil- related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer letters (in press)